Last reviewed · How we verify
THN102 Dosage C
At a glance
| Generic name | THN102 Dosage C |
|---|---|
| Also known as | Dosage C |
| Sponsor | Theranexus |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THN102 Dosage C CI brief — competitive landscape report
- THN102 Dosage C updates RSS · CI watch RSS
- Theranexus portfolio CI